Patent ID: 6627458
Filing Date: 2003-09-30
Classification: C07K,G01N

Abstract:
A method for determining whether a human subject is diseased with ulcerative colitis, primary sclerosing cholangitis or autoimmune hepatitis which comprises:(a) obtaining a suitable body fluid from a human subject; (b) contacting the suitable body fluid from the human subject with a nuclear envelope protein of neutrophils and myeloid cells having an apparent molecular weight of about 50,000 Daltons as estimated by SDS-polyacrylamide gel electrophoresis, an isoelectric point of approximately pH 6.0, and is capable of binding with a typical p-antineutrophil cytoplasmic antibodies (a typical p-ANCA), so as to bind a typical p-ANCA in the suitable body fluid to the said protein; (c) immunodetecting the bound a typical p-ANCA of step (b); and (d) determining the titer of a typical P-ANCA present in the suitable body fluid, wherein a titer in the range of about 1:160 to about 1:2560 indicates the human subject is diseased with ulcerative colitis, a titer in the range of about 1:2560 to about 1:5120 indicates the human subject is diseased with primary sclerosing cholangitis and a titer in the range of about 1:5120 to about 1:10240 indicates the human subject is diseased with autoimmune hepatitis.